Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00569972 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 682
- Enrollment target
NCT00569972 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 682 participants.
The verdict
NCT00569972, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 682 participants
- Enrollment target
Study Summary
To demonstrate efficacy and characterize the dose response relationship of PD 0200390 on subjective wake after sleep onset in subjects with primary insomnia.
Interventions
- DRUG Placebo
- DRUG PD 0200390
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 682 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00569972
The ClinicalTrials.gov registry entry for NCT00569972 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 682 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00569972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00569972 about?
NCT00569972 is a clinical study titled "A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia". To demonstrate efficacy and characterize the dose response relationship of PD 0200390 on subjective wake after sleep onset in subjects with primary insomnia.
What is the current status of trial NCT00569972?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 682 participants. The study started on 2007-10. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00569972?
The interventions under investigation include: Placebo (DRUG), PD 0200390 (DRUG).
Who is sponsoring clinical trial NCT00569972?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.